Propanamide, N-(2,6-dinitro-4-(trifluoromethyl)phenyl)-N-propyl- | 69236-56-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Propanamide, N-(2,6-dinitro-4-(trifluoromethyl)phenyl)-N-propyl-
• 英文别名: N-[2,6-dinitro-4-(trifluoromethyl)phenyl]-N-propylpropanamide
• CAS: 69236-56-2
• 化学式: C13H14F3N3O5
• 分子量: 349.26
• InChiKey: VFTBFWNODJPOJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  112
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS
  申请人：Seattle Children's Hospital (dba Seattle Children's Research Institute)

  公开号：US20200087399A1

  公开（公告）日：2020-03-19

  Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
• METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS
  申请人：Seattle Children's Hospital (dba Seattle Children's Research Institute)

  公开号：US20210317407A1

  公开（公告）日：2021-10-14

  Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.
• [EN] PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS<br/>[FR] AGENTS DE CIBLAGE DE TUMEUR À LYMPHOCYTES T CAR (CTCT) D'ÉTHER DE PHOSPHOLIPIDE (PLE)
  申请人：SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST

  公开号：WO2018148224A1

  公开（公告）日：2018-08-16

  Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
• [EN] ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN<br/>[FR] PROTÉINES DE FUSION INDUCTIBLES PAR ACTIVITÉ AYANT UN DOMAINE DE LIAISON À LA PROTÉINE DE CHOC THERMIQUE 90
  申请人：[en]SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE

  公开号：WO2022174035A2

  公开（公告）日：2022-08-18

  Activity-inducible fusion proteins whose activity is post-translationally regulated utilizing a hsp90 binding domain and a drug molecule are described. In the absence of the drug molecule, the activity-inducible fusion proteins are inactivated but can be activated by a relevant physiological parameter in the presence of the drug molecule. Examples of the activity-inducible fusion proteins include chimeric antigen receptors (CAR) wherein the relevant physiological parameter is antigen binding.